NEWS

news

Research published in Genome Medicine details a novel and promising approach in the effort to treat Alzheimer's disease. Brigham Young University professors Perry Ridge and John Kauwe led the discovery of a rare genetic variant that provides a protective effect for high-risk individuals

news

Pfizer and Basilea Pharmaceutical Ltd, an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive development

news

Researchers from the Bio-gerontology Research Foundation, Insilico Medicine, Life Extension and other institutions announce the publication of a landmark study in the journal aging on the identification of natural mimetics of metformin and rapamycin. Metformin, a common type 2 diabetes

news

AstraZeneca will sell the remaining rights to its anaesthetic medicines portfolio to Aspen Pharmacare in a deal worth up to $766 million. Last year, the company sold rights to its global anaesthetics portfolio outside the US to Aspen under a $770-million agreement.

news

The US Food and Drug Administration has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.

news

Scientists at The Scripps Research Institute (TSRI) have made a discovery that could speed efforts to develop a successful HIV vaccine.The scientists found that on the HIV envelope protein, at a site important for viral function, a small group of sugar molecules, known as glycans, serves as a key "anchor" for antibodies that can broadly neutralize the virus.

news

As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.

news

The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.

news

Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute (NCI) study evaluating the safety and efficacy of a MAGE A3 T cell receptor (TCR) engineered T-cell therapy. The cancer testis antigen MAGE A3 is frequently found in many cancers including bladder, esophageal, cervical, head and neck, lung, and ovarian cancers, among others. The research, led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at NCI's Center for Cancer Research, was performed, in part, pursuant to a Cooperative Research and Development Agreement (CRADA) between NCI and Kite.

news

ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the completion of enrolment for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential genetically-targeted treatment for atrial fibrillation (AF). ARCA expects to report top-line Phase 2B data late in the first quarter of 2018.

news

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite.

news

Cancer Research UK and Newcastle University have extended their strategic drug discovery alliance with Astex Pharmaceuticals by three years to work on developing new cancer drugs and associated biomarkers.The alliance, formed five years ago, brings together researchers in structural and cellular biology

news

The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes

news

A new collaboration agreement between Cancer Research UK and Biotecnol will see an experimental immuno-oncology treatment move into early phase clinical trials for patients with advanced solid tumours, including lung cancers. lymphoblastic leukaemia (ALL).B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes

news

The government has privately raised objections to Chinese firm Shanghai FosunPharmaceutical Group's proposed $1.3-billion takeover of drug maker Gland Pharma, a source familiar with the matter said on Monday. The deal has won the approval of the Competition Commission of India (CCI), and the Foreign Investment Promotion Board (FIPB) in the last few months

news

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.Under the initiative, the MRC will fund up to five projects a year giving UK academic scientists access to UCB’s technologies in order to facilitate the potential discovery of new monoclonal antibodies, that can then be used to research the mechanisms of disease and identify novel therapeutic targets.

news

Published today in Genome Research, the study examined a large collection of E. coli isolated from patients with bloodstream infection over more than a decade, some of which were resistant to numerous antibiotics while others were not.

news

The work could lead to a new generation of potential therapies for NPC1 and other similar disorders, as well as neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. The scientists reported their findings online on July 17, 2017 in the journal Autophagy.

news

Researchers from MIT and other institutions are hoping to use nanotechnology to develop more targeted treatments for these drug-resistant bugs. In a new study, they report that an antimicrobial peptide packaged in a silicon nanoparticle dramatically reduced the number of bacteria in the lungs of mice infected with Pseudomonas aeruginosa, a disease causing Gram-negative bacterium that can lead to pneumonia.

news

Imagine a drug regimen where an obese person would cycle between different drug therapies over the course of a month to achieve a greater degree of body weight loss compared to the effects achieved with either a single drug or the continuous combination of drugs," said senior author Dr. Matthew Hayes.

news

NEW YORK, June 29 (Reuters Breaking views) - New commissioner Scott Gottlieb is wasting no time combating high prices. The U.S. agency will expedite reviews of generic-drug applications to promote competition. The changes will batter the likes of Valeant and Cardinal Health, and cast a cloud over branded drug makers.

news

Hyderabad, Jun 26 () Takeda Pharmaceutical Company and Biological E Ltd (BE) have signed two licensing agreements for development and delivery of affordable combination vaccines for low and middle-income countries.

news

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) requested an additional clinical study as part of a complete response letter (CRL) to the company’s new drug application for lifitegrast for the signs and symptoms of dry eye disease in adults.

news

VistaGen Therapeutics Inc , a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders announced it has signed an exclusive sublicense agreement with BlueRock Therapeutics

news

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

news

Neurim Pharmaceuticals and Exeltis announced a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim’s new Rx PedPRM in Spain.

news

Steel trade groups representing Canada, the United States and Mexico said that any upgrade to the North American Free Trade Agreement (NAFTA) should require that manufacturers use more steel produced in the region in their products. The rules of origin, which stipulate that products must meet minimum NAFTA-wide content requirements…

news

Ireland’s Government is to invest €5m over the next five years in a new Pharmaceutical Manufacturing Technology Centre (PMTC) that will be headquartered at the University of Limerick.